High-Risk HPV16 E6 Activates the cGMP/PKG Pathway Through Glycosyltransferase ST6GAL1 in Cervical Cancer Cells

Jun Wang†, Gao Liu†, Mei Liu†, Qinzhen Cai†, Cong Yao§, Hao Chen§, Neng Song§, Chunhui Yuan†, Decai Tan*, Yuhai Hu*, Yun Xiang† and Tian Xiang**

† Department of Laboratory Medicine, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China, ‡ Department of Gastrointestinal Surgery, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College, Medical School of Hubei Minzu University, Enshi, China, § Department of Laboratory Medicine, Wuhan Hankou Hospital, Wuhan, China, * Health Care Department, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China, † Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China, ‡ Department of Laboratory Medicine, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, China, † Department of Science and Education, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College, Medical School of Hubei Minzu University, Enshi, China, ** Department of Laboratory Medicine, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College, Medical School of Hubei Minzu University, Enshi, China

Alterations in glycosylation regulate fundamental molecular and cellular processes of cancer, serving as important biomarkers and therapeutic targets. However, the potential association and regulatory mechanisms of E6 oncoprotein on glycosylation of cervical cancer cells are still unclear. Here, we evaluated the glycomic changes using Lectin microarray and determined the corresponding enzymes associated with endogenous high-risk HPV16 E6 expression in cervical cancer cells. α-2,6 sialic acids and the corresponding glycosyltransferase ST6GAL1 were significantly increased in E6 stable-expressing HPV− cervical cancer C33A cells. Clinical validation further showed that the expression of ST6GAL1 was significantly increased in patients infected with high-risk HPV subtypes and showed a positive association with E6 in cervical scraping samples. Interfering ST6GAL1 expression markedly blocked the oncogenic effects of E6 on colony formulation, proliferation, and metastasis. Importantly, ST6GAL1 overexpression enhanced tumorigenic activities of both E6-positive and E6-negative cells. Mechanistical investigations revealed that E6 depended on activating YAP1 to stimulate ST6GAL1 expression, as verteporfin (inhibitor of YAP1) significantly suppressed the E6-induced ST6GAL1 upregulation. E6/ST6GAL1 triggered the activation of downstream cGMP/PKG signaling pathway and ODQ (inhibitor of GMP production) simultaneously suppressed the
INTRODUCTION

Cervical cancer remains the fourth most frequently diagnosed cancer and the fourth leading cause of cancer-related deaths among women worldwide (1). The major causative factor that leads to the development of cervical cancer has been identified as human papillomavirus (HPV) persistent infection (2). High-risk HPV16 is the most common carcinogenic HPV subtype and is responsible for more than half of cervical cancers (3–5). Due to the wide coverage of cancer screening and HPV vaccination programs, incidence and mortality rates of cervical cancer have progressively declined in well-developed countries (6), but an increasing incidence and mortality trend is observed in China, especially in young women (7). Furthermore, the vaccine ISA101, one of the most promising therapeutic vaccines that directly targeted the HPV16 E6 and E7 oncoproteins, has been shown to be ineffective for invasive cancer by itself alone (8).

In infected malignant cells, HPV16 genome frequently (>76%) integrated into the host cell DNA (9). The E6 oncoprotein is one major driver of oncogenesis in the normal cervical epithelium and plays important roles for controlling epithelial differentiation, cellular growth, and immune function (10, 11). Mechanistically, E6 forms a complex with host E3 ubiquitin ligases and mediates proteasomal degradation of a number of host targets, such as tumor suppression protein p53 (12), and also increases telomerase activity to prevent apoptosis and promote the immortalization of infected cells (13). Specifically, E6 protein of high-risk HPV16 and HPV18 can further bind and regulate a selection of PSD95/DLG/ZO-1 (PDZ) domain-containing proteins, like DLG1 and SCRIB, to increase oncogenic potential (14). However, HPV16 E6 preferentially binds SCRIB over DLG1 and vice versa for HPV18 E6. Furthermore, HPV16 E6 also promotes NHERF1 degradation to enhance the metastasis of cervical cancer cells, whereas NHERF1 is not targeted by HPV18 E6 (15). Recently, disruption of the direct interaction between E6 and host proteins or chimeric antigen receptor T cells (CAR-T cells) targeted to E6 have been shown to be effective for HPV16 cervical cancers (16, 17). Thus, a further detailed clarification of the oncogenic molecular mechanisms of high-risk HPV16 E6 would be beneficial for the development of therapeutic interventions directed against HPV16 malignancies.

Glycosylation alterations frequently occurred in tumor cells and participate in numerous fundamental biological processes, including cellular signaling, proliferation, adhesion, extracellular matrix interactions, proximal and distal communication, inflammation, and immune surveillance (18). For example, with the ability to enhance the biosynthesis of poly-N-acetyllactosamine chains and generation of the backbone components of dimeric sialyl Lewis A, B3GNT3/B3GNT2-mediated glycosylation of both PD-L1 and PD-1 enhances their interaction, and downregulation of these enzymes represents a potential strategy to enhance immune checkpoint therapy (19–21). Sialylation is another important abnormal glycan modification found in the vast majority of cancers, which leads to the hyperactivation of the receptor tyrosine kinases (RTKs), like epidermal growth factor receptor (EGFR), MET, and RON (22, 23). Increased expression of β-galactoside α2,6-sialyltransferase I (ST6GAL1), an enzyme generated α2,6-sialylated lactosamine, is often associated with invasive phenotype and poor prognosis in several cancers, including colon, stomach, and ovarian cancers (24). Moreover, ST6GAL1 endows resistance of cancer cells to gefitinib (EGFR inhibitor) and trastuzumab (anti-ErbB2 antibody) and also predicts the sensitivity of lenvatinib treatment to patients with hepatocellular carcinoma (25). Thus, targeting glycosylation alterations holds potent promise to augment the available strategies in both therapy and biomarker field of cancers.

Recently, increased sialylation, GlcNAcylation, and reduced fucosylation have been found to be upregulated in carcinomas of the cervix (26–28) and patients with metastatic cervical cancer (29). However, the glycosylation alterations of cervical cancer in response to high-risk HPV16 E6 stimulation, and the potential regulatory mechanisms remain largely unknown. In the present study, we confirmed that E6 increases level of α2-6 sialic acids in cervical cancer HPV− C33A cells via using Lectin microarray, and ST6GAL1 is an important mediator for E6 to perform oncopgenic activities. In details, E6 depends on activating YAP1 and their interaction, and downregulation of these enzymes might potent promise to augment the available strategies in both therapy and biomarker field of cancers.

Materials and Methods

Cell Culture

The human embryonic kidney (HEK293T) cells, C33A (HPV−) cells, were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China) as we previously described (30). HEK293T cells and C33A and C33A-E6 cells were grown in...
Phosphate-buffered saline (PBS) Dulbecco’s modified Eagle’s medium (DMEM)–low glucose (Gibco, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Beyotime, Shanghai, China) under a humidified atmosphere containing with 5% CO2 at 37°C.

Collection of Cervical Specimens
Samples of all patients were collected with a clinically approved disposable cervical abscission cell sampler (158-0001, Kang Jian Medical, Jiaxing, China). The instructions for use of these cervical sampling brush were as follows: expose the cervix, wipe off the secretions with a cotton swab, carefully insert the brush head into the endocervical canal until the outer bristles touch the outer cervical neck, rotate clockwise five to eight times, and finally insert the brush head into the preservation solution bottle. Genomic DNA was first extracted from the collected samples using a DNA extraction kit (Chaozhou Hybribio Biochemical Co., Ltd., Chaozhou, China) according to the manufacturer’s instructions. According to the clinical detection results of HPV typing as we presented in our previous study (31), 10 samples of five groups were collected respectively and stored at −80°C, and then, ST6GAL1 and E6 gene tests were performed. The five groups including (1) single HPV16-positive specimens, (2) mixed HPV16-positive specimens, (3) other high-risk HPV-positive specimens, (4) low-risk HPV-positive specimens, and (5) HPV-negative specimens. The overview of the clinical characteristics of patients are shown in Supplementary Table S1. The study was approved by the Institutional Review Board of the Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital) (2020R079-E01).

Lentivirus Production and Transduction
HPV16 E6 stable-expressing C33A cells were constructed according to our previous study (32). In brief, HPV16 E6 (GenBank accession no. FJ415228.1) was cloned into the lentiviral backbone plLVX-mCMV-ZsGreen-IRE5-Puro. Then, the plasmids, pCAG-HIVgvp (RDB04394, Riken, Japan) and pCMV-VSV-G-RSV-Rev (RDB04393, Riken, Japan), were simultaneously transfected into HEK293T using Lipofectamine 2000 (Invitrogen, Shanghai, China) following the manufacturer’s instruction. Forty-eight hours after transfection, the selective overexpression or silencing of ST6GAL1 was detected by Western blot.

mRNA Sequencing
Total RNA was extracted from C33A and C33A-E6 cells with Trizol reagent (Invitrogen, CA, USA). Then, the RNA was quantified using a NanoDrop ND-2000 (Thermo Scientific), and its integrity was assessed using the Agilent Bioanalyzer 2100 (Agilent Technologies, USA). Next, the mRNA molecules were purified from the total RNA using oligo (dT) magnetic beads and fragmented into small pieces and then subjected to transcriptome analysis (OEbiotech, Shanghai, China). The E6-dysregulated mRNAs were identified by the combination of the absolute value of the [log2 [fold change of reads per kilo base per million mapped reads (RPKM)] ≥ 1 and p < 0.05. ST6GAL1-associated mRNAs were analyzed using R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) as we previously described (32); the cutoff correlation p-value was < 0.01. Cluster Profiler R package was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. MEV software was used for hierarchical cluster analysis of mRNA expression according to the protocol provided by OEbiotech.

Quantitative Real-Time PCR
Total RNA extracted from indicated cervical cancer cells with Trizol reagent (Invitrogen, CA, USA). Subsequently, complementary DNA was generated from 1 µg total RNA
using Prime Script RT Master Mix (Takara Bio Inc., Kusatsu, Japan). Real-Time PCR (qRT-PCR) was conducted using 2× SYBR green PCR master mix (TaKaRa, Dalian, China) according to the manufacturer’s protocol to detect mRNA levels of indicated genes. The ABI 7500 (Applied Biosystems, CA, USA) was used to perform the amplification reaction. Each experiment was performed in triplicate. Gene expression values were normalized relative to expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by the 2^−ΔΔCt method. The gene-specific primer sequences are listed in Table 1.

**Western Blot**
Cells were lysed on ice with radioimmunoprecipitation assay (RIPA) buffer (Beyotime, China) containing a protease inhibitor cocktail. The concentration of protein was detected by a BCA protein assay kit (Beyotime). Protein samples (30 µg) were separated by 8% SDS-PAGE gel electrophoresis and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, MA, USA) for subsequent experiments. The membranes were blocked by 5% defatted milk for 2 h at room temperature and then incubated with primary antibodies against HPV16E6 (sc-460; 1:1,000; 16 kDa; Santa Cruz), ST6GAL1 (14355-1-AP; 1:1,000; 47 kDa; Proteintech), B3GNT2 (sc-13423; 1:1,000; 46 kDa; Santa Cruz), FUT1 (sc-100742, 1:1,000; 39 kDa; Santa Cruz), B4GALT1 (sc-515551, 1:1,000; 50 kDa; Santa Cruz), Bcl-2 (ab196495; 1:1,000; 26 kDa; Abcam), BAX (50599-2-lg; 1:10,000; 21 kDa; Proteintech), p53 (ab26; 1:1,000; 53 kDa; Abcam), YAP1 (ab56701; 1:1,000; 49 kDa; Abcam), p-YAP1 S397 (#13619; 1:1,500; 75 kDa; CST), VASP (13472-1-AP; 1:1,000; 46 kDa; Proteintech), p-VASP S547 (ab194747; 1:1,000; 40 kDa; Abcam), Smad2 (ab119907; 1:1,000; 52 kDa; Abcam), p-Smad2 S897 (ab53100; 1:1,000; 47 kDa; Proteintech, Abcam), Smad2 (ab119907; 1:1,000; 46 kDa; Santa Cruz), B4GALT1 (sc-515551, 1:1,000; 50 kDa; Santa Cruz), E-cadherin (13-1700; 1:1,000; 110 kDa; CST), VASP (13472-1-AP; 1:1,000; 46 kDa; Proteintech), p-VASP S547 (ab194747; 1:1,000; 40 kDa; Abcam), Smad2 (ab119907; 1:1,000; 52 kDa; Abcam), p-Smad2 S897 (ab53100; 1:1,000; 47 kDa; Abcam), E-cadherin (13-1700; 1:1,000; 110 kDa; Invitrogen), sGC (ab189176, 1:1,000; 71 kDa; Abcam),PKG1 (#3248, 1:1,000; 48 kDa; CST), PKG2 (55138-1-AP; 1:1,000; 87 kDa; Proteintech), PDE5A (ab28876; 1:1,000; 95 kDa; Abcam), and GAPDH (sc-47724; 1:1,000; 37 kDa; Santa Cruz) at 4°C overnight. Next, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies and visualized by chemiluminescence (Pierce ECL Western Blotting Substrate).

**Cell Counting Kit-8 Assay**
Cells (1.5 × 10^4) were plated into 96-well plates and incubated with 5% CO2 at 37°C, after incubation for 24, 48, 72, and 96 h, 10 µl Cell Counting Kit-8 (CCK-8) reagent (Yeasen, Shanghai, China) was added into each well and incubated for another 4 h. Cell viability was assessed by detecting the absorbance of the dye solution at 450 nm in a microplate reader (Bio-Rad, CA, USA). All samples were prepared in triplicate and normalized to a blank control.

**Colony Formation Assay**
Cells (1 × 10^5) were plated in six-well plates for 24 h and then received indicated transfection or drug treatment. Cells were then cultured in fresh medium for another week. Colonies were fixed with methanol and stained with crystal violet (0.05%, w/v) for 30 min. Photographs were acquired, and colonies containing more than 50 cells were counted. All the experiments were performed in triplicate.

**Cell Apoptosis Assay**
For cell apoptosis analysis, cells were incubated with Annexin V-FITC and propidium iodide using an Annexin V-FITC Apoptosis Detection Kit (Biolegend) according to the manufacturer’s protocol at 4°C in the dark for 30 min. The fluorescence of the stained cells was examined by flow cytometry (FACSCanto II, Becton-Dickinson, USA) and analyzed by FlowJo 10.5.4 software.

**Wound-Healing Assay**
A wound-healing assay was used to evaluate the migration of C33A and C33A-E6 cells. Briefly, cells (1 × 10^4) were seeded in 24-well plates for growth to 80–90% confluence. Then, the monolayers were wounded by scratching the surface as uniformly as possible with a pipette tip. The remaining cells were washed thrice in phosphate-buffered saline (PBS) to remove cellular debris and incubated at 37°C with serum-free medium. Migrating cells at the wound front were photographed under an Olympus IX73 microscope after 24 h. The area of the wound was measured with ImageJ software (NIH, USA).

**Table 1** Primer sequences for genes.

| Gene   | Forward primer (5′-3′)                                           | Reversed primer (5′-3′)                                           |
|--------|----------------------------------------------------------------|----------------------------------------------------------------|
| HPV16E6 | ATGACCACAAAAGAAGAAGACTGCACATGT                                          | TTAACAGCTTGTTTTCCTCTACTGTCGT                                           |
| B3GALNT1 | CTGCTGAGTTTCTCTGTGATGTGGA                                          | CATTAGCTAGTTTGATGTGAG                                                    |
| B4GALNT1 | GGAACGTGGGGGCTTTGCTCTCAAGTAGCAC  | CAGCAGGAAGAAGTTACAGCGCCGTC                                              |
| ST6GAL1  | CTACCATGCGGGTTATGTCGATACCTGT                                        | TCTGGGGCGGTAGGATGAAAAG                                                  |
| ST6GAL2  | CGTAAGGGAGGGTTATGCTGATATGCCC                                        | ACCTCGAGGTAGCTGCTAGTATAC                                             |
| MAN2A1   | TTAAAGGCGGACAGTTCACCCG                                               | ACATTTAGAGCAGTGGCGCCGTAGG                                              |
| B4GALT1  | TGAGTTAACATGCTGGTGGACCTG                                            | GTCGTCGTCGTCGCGGCGCCTAGG                                              |
| FUT1     | ATTAGGTCAGCAAGCCGCGGCGCGACTG                                        | ATGCGACGCTGCGGCGGCGCGGCGCAGAAGG                                  |
| FUT2     | GTCAAGGGAGGTCAAGGTTT                                                | GTCCGTCGTCGCGGCGGCGGCGGCGCAGAAGG                                  |
| B3GNT3   | TATGTGCTCAGCTGCTGAG                                                  | AAGGATGCTGAGTGGCGGCGGCGGCGCAGAAGG                                  |
| B3GNT2   | CTGTGCTCCGCGAGAATATGA                                               | GTCGTCGTCGCGGCGGCGGCGGCGCAGAAGG                                  |
| GAPDH    | CGGGCGGAAAAGGCGCTAT                                                  | GADTCCTTTCGAGCGAAGGGAGAGG                                       |
Transwell Assay
Transwell assay was used to investigate cells invasion in C33A and C33A-E6 cells as we described previously (30, 32). Briefly, 24-well Transwell plates (pore size, 8 µm; Corning, Inc.) with 100 µl Matrigel (BD Biosciences) in upper chamber were used for cell invasion assays. Cells (5 × 10⁴) were resuspended in serum-free medium and placed into the upper chamber. Complete medium in the lower chamber was considered as a chemical attractant. After incubating for 24 h, the invaded cells attached to the lower surface were fixed with 4% formaldehyde for 15 min and then stained with 0.05% crystal violet for 30 min. The invasion cells were photographed under an Olympus IX73 microscope. Experiments were performed in three independent times and six random fields were scanned in each time.

Statistical Analysis
The data were presented as mean ± standard deviation of at least three independent experiments and analyzed by GraphPad Prism 8.0 Software (GraphPad Software Inc., La Jolla, CA, USA). Unpaired t-test or one-way ANOVA followed by Newman–Keuls post-hoc test was performed for data analysis. A p < 0.05 was considered as statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).

RESULTS
The High-Risk HPV16 E6 Protein Results in Altered Glycosylation in Cervical Cancer Cells
To examine the relationship between HPV16 E6 and altered glycosylation in cervical cancer, we constructed HPV16 E6-stable expressing HPV C33A cervical cancer cells (C33A-E6) and detected the glycan repertoire of cellular glycoproteins via using 95-lectins microarray. In general, C33A-E6 cells showed higher levels of α-2,6 sialic acids (bound by lectin SNA-I), N-acetylgalactosamine (WFA, SHA), α-1,3- and α-1,6-linked mannose (HHA, NPL), β-galactosidase (GAL9), and lower levels of lactose/galactose (RCA120, RCA60, PHA-E), and α-1,2 fucose structures (UEA-I) than the corresponding control C33A cells (Figures 1A, B; Table 2). To gain insight into the biosynthetic underpinnings of these changes, we then focused on glycogenes (glycosyltransferases) known to be involved in the synthesis of glycan epitopes bound by these lectins. Consistent with our observed glycan changes, C33A-E6 cells displayed higher expression levels of N-acetylgalactosamine branching enzymes (B3GALNT1 and B4GALNT1), sialyltransferases (ST6GAL1 and ST6GAL2), and α-1,3- and α-1,6-linked
mannose extension enzymes (MAN2A1) than control C33A cells, and lower levels of lactose/galactose branching enzyme B4GALT1 and α,1,2 mannosidases (FUT1 and FUT2) (Figures 1C, D). In addition, poly-N-acetyllactosamine (DSA, WGA) and its corresponding enzymes (B3GNT2 and B3GNT3) showed no changes (Figures 1A–D). These results indicate that E6 results in altered glycosylation in cervical cancer cells. Given the strong evidence for a relationship between the glycosylation and cancer progression (18), we hypothesized that altered expression of these glycogenes and their corresponding changes in glycan epitopes may be involved in the oncogenic activities of HPV16 E6.

**ST6GAL1 Is a Pivotal Oncogenic Mediator of the High-Risk HPV16 E6**

Knockdown of ST6GAL1 suppresses subcutaneous tumor growth and increases cisplatin sensitivity of cervical cancer cells (35); we therefore presumed that ST6GAL1 may be a candidate oncogenic mediator of HPV16 E6 protein. To validate this speculation, we first detected ST6GAL1 expression in cervical scraping samples of patients with different subtypes of HPV infection. The expression of ST6GAL1 was significantly higher in patients infected with high-risk HPV subtypes, including HPV16+, HPV18+, or others (Figure 2A). Moreover, Ct value of ST6GAL1 showed a positive association with E6 in E6-detected cervical scraping samples (Figure 2B). Then, ST6GAL1 was silenced in both C33A and C33A-E6 cells via transient transfecting with short-hairpin RNA targeting ST6GAL1 (shST6GAL1) or a non-targeting control (shNTC) (Figure 2C). CCK-8 and clonogenic assays revealed that ST6GAL1 knockdown markedly attenuated the oncogenic effects of E6 on cellular proliferation (Figure 2D) and colony formulation (Figures 2E, F). Comparing to shNTC-transfected C33A-E6 cells, the apoptotic rate (Figures 2G, H) and expression of proapoptotic proteins, Bax and p53, were also significantly increased in cells transfected with shST6GAL1, and antiapoptotic factor Bcl-2 was significantly decreased (Figure 2I). Furthermore, ST6GAL1 knockdown significantly attenuated the metastatic potential of C33A-E6, including migration (Figures 2J, K) and invasion (Figures 2L, M) in wound-scratching and Transwell assays. Therefore, these data demonstrate that ST6GAL1 is a pivotal mediator for E6 to perform oncogenic activities in cervical cancer cells.

**ST6GAL1 Promotes Oncogenic Activities in Both E6-Positive and E6-Negative Cervical Cancer Cells**

Knockdown of ST6GAL1 suppresses the oncogenic activities of HPV18+ Hela cells (35) and also HPV− C33A cells (Figure 2). To further confirm the oncogenic potential of ST6GAL1 with or without the status of HPV infection, we then transiently overexpressed ST6GAL1 in both C33A and C33A-E6 cells (Figure 3A). Cellular proliferation (Figure 3B) and colony formulation (Figures 3C, D) of both C33A and C33A-E6 cells were significantly increased in response to ST6GAL1 overexpression. In addition, overexpression of ST6GAL1 also significantly decreased the apoptotic rates (Figures 3E, F) and the expression of proapoptotic proteins, Bax and p53 (Figure 3G) in both C33A and C33A-E6 cells. Antiapoptotic protein Bcl-2 was significantly increased in response to ST6GAL1 overexpression (Figure 3H). With regard to the metastatic potential, ST6GAL1 overexpression significantly increased migrating (Figures 3I, J) and invading (Figures 3J, K) abilities of both C33A and C33A-E6 cells as revealed in wound-scratching and Transwell assays. Taken together, these data demonstrate a crucial oncogenic role of ST6GAL1 in both E6-positive and E6-negative cervical cancer cells.

**HPV16 E6 Promotes ST6GAL1 Expression by Activating YAP1**

To identify the potent regulatory mechanism of HPV16 E6 on ST6GAL1, mRNA sequencing was performed on both C33A and C33A-E6 cells, and the results showed that E6-stable expression resulted in dysregulation of 658 mRNAs, including 439 upregulated and 219 downregulated mRNAs (Figures 4A, B). Importantly, 466 of 658 mRNAs were significantly associated with ST6GAL1 expression together with or without the status of HPV infection (Figures 4C). KEGG enrichment analysis revealed that these 466 mRNAs were mainly involved in glycan biosynthesis, pathways in cancer, and TGF-β, cGMP/PKG, and Hippo signaling pathways (Figure 4D). Next, selective enzyme inhibitors were used to examine which signaling pathway mediated the upregulation of ST6GAL1 in C33A-E6 cells. The mRNA expression of ST6GAL1 was significantly suppressed with the presence of verteporfin, an inhibitor of YAP1 in the Hippo signaling, whereas cGMP/PKG inhibitor ODQ and TGF-β inhibitor LY-364947 showed no obvious effects (Figure 4E). E6 stable expression in C33A cells significantly suppressed Ser397-

---

**TABLE 2 | Differences in glycan patterns between C33A and C33A-E6 cells by lectin microarray analysis.**

| Lectin                      | Abbreviation | Carbohydrate specificity | Glycosyltransferase | Fold change (C33A-E6 vs. C33A) | p     |
|-----------------------------|--------------|--------------------------|---------------------|-------------------------------|-------|
| Sambucus nigra l            | SNA-I        | α-2,6 sialic acid         | ST6GAL1, ST6GAL2    | 3.13                          | 0.0099|
| Wisteria floribunda         | WFA          | GalNAc                   | B3GALNT1, B4GALNT1  | 2.62                          | 0.022 |
| Salvia horminum lectin      | SHA          | GalNAc                   | B3GALNT1, B4GALNT1  | 1.11                          | 0.0106|
| Hippeastrum hybrid          | HHA          | α-1,3-Linked mannose      | MAN2A1              | 1.95                          | 0.0299|
| Narcissus pseudonarcissus   | NPA          | α-1,6-Linked mannose      | MAN2A1              | 2.19                          | 0.0179|
| Ulex europaeus I            | UEA-I        | α-1,2-Fucose structures   | FUT1, FUT2         | 0.58                          | 0.0364|
| Ricinus communis agglutinin | RCA 120      | Galactose, lactose        | B4GALTL1           | 0.17                          | 0.005 |
| Ricinus communis agglutinin | RCA 60       | Galactose, lactose        | B4GALTL1           | 0.46                          | 0.0191|
| Phaseolus vulgaris erythroagglutinin | PHA-E | galactose                  | B4GALTL1           | 0.64                          | 0.0238|

---

**Figure 1**

**Figure 2**

**Figure 3**

**Figure 4**
phosphorylated YAP (degradation status) and enhanced total YAP expression (Figure 4F). Consistent with mRNA results, only the addition of verteporfin significantly downregulated ST6GAL1 protein expression in both C33A and C33A-E6 cells (Figure 4F) but not ODQ (Figure 4G) and LY-364947 (Figure 4H). Thus, these findings provide compelling evidence that activation of YAP1 is critical to ST6GAL1 expression and is a major mediator of E6-induced ST6GAL1 upregulation.

ST6GAL1 Activates cGMP/PKG Signal Axis to Play Oncogenic Activities

We next examined the effects of ST6GAL1 on TGF-β, cGMP/PKG, and Hippo signaling pathways. The phosphorylation of VASP (a major effector indicates cGMP/PKG signaling activation) and Smad was significantly increased by ST6GAL1 overexpression and vice versa for ST6GAL1 knockdown (Figure 5A). The expression of E-cadherin was significantly reduced, and YAP1 expression showed no response to ST6GAL1 overexpression (Figure 5A). These results indicated that ST6GAL1 activates both cGMP/PKG and TGF-β signaling.

Activation of cGMP/PKG promotes chemoresistance and maintenance of cancer stem cells in cervical, breast, ovarian, and gastric cancers (32, 36). Thus, we further investigated the therapeutic potential of cGMP/PKG inhibitor ODQ on ST6GAL1 overexpression. The ST6GAL1-enhanced cellular proliferation (Figure 5B) and colony formation (Figures 5C, D) of C33A cells were significantly suppressed by ODQ treatment. In addition, ODQ also significantly promoted apoptosis (Figures 5E, F) and blocked the migration (Figures 5G, H) and invasion (Figures 5I, J) of ST6GAL1-overexpressing cells. Taken together, these results demonstrate that ST6GAL1 depends on activating cGMP/PKG signaling axis to play oncogenic activities in C33A cervical cancer cells.

HPV16 E6 Activates cGMP/PKG Signaling Pathway Through ST6GAL1

The activation of cGMP/PKG signaling plays oncogenic roles in both HPV16+E6 Siha and HPV18+Hela cells (37). Thus, we further evaluated whether HPV16 E6 activates cGMP/PKG signaling and the role of ST6GAL1 in this process. As expected, the
molecules indicate that cGMP/PKG signaling activation, including sGC, PKG1, PKG2, PDE5A, and p-VASP, was significantly upregulated by E6-stable expression in HPV− C33A cells (Figure 6A). ST6GAL1 knockdown markedly attenuated E6-induced activation of cGMP/PKG signaling, and its overexpression further elevated p-VASP levels in C33A-E6 cells (Figure 6B). These results indicate that HPV16 E6 activates cGMP/PKG signaling in cervical cancer cells, and ST6GAL1 is critical for this process. The effects of ODQ on E6-mediated oncogenic activities were next evaluated, and the results revealed that ODQ significantly suppressed cellular proliferation (Figure 6C) and colony formulation (Figures 6D, E) in both C33A and C33A-E6 cells. The apoptotic rates were also increased in response to ODQ treatment (Figures 6F, G). Furthermore, the migration (Figures 6H, I) and invasion (Figures 6J, K) of both C33A and C33A-E6 cells were significantly decreased with the presence of ODQ. Taken together, these data demonstrate a requirement for ST6GAL1-cGMP/PKG signaling axis in oncogenic properties of E6 and supports its inhibition as a viable therapeutic strategy against cervical cancer.

DISCUSSION

HPV16 E6 oncoprotein plays multifunctional roles on post-translational modifications (PTMs), including ubiquitination, acetylation, and phosphorylation, and thereby contributes to the viral life cycle and to the induction of malignancy (38–40). Serving as an important kind of PTMs, glycosylation can act as a key regulatory mechanism to control cancer progression and highlight its application in the clinical setting as appealing targets for personalized medicine (41). However, the glycosylation alterations that associated with HPV infection and their role in controlling the progression of cervical cancer remain largely unknown. In the present study, our results confirmed that HPV16 E6 oncoprotein induces significant glycosylation alteration.
alterations in HPV−C33A cells via 95-lectins microarray, including increased expression of α-2,6 sialic acids (corresponding glycotransferases, ST6GAL1, ST6GAL2), α-1,3- and α-1,6-linked mannose (MAN2A1), and N-acetylgalactosamine (B3GALNT1, B4GALNT1), and decreased levels of lactose/galactose (B4GALT1) and α-1,2 fucose structures (FUT1, FUT2).

Remarkably, numerous studies have confirmed that these glycosylation alterations induced by E6 stable expression play important roles in modulating cancer signaling, tumor progression, metastasis, antitumor immunity, and responses of current cancer-targeted therapies (18). For example, FUT1 and FUT2 promote growth, adhesion, migration, and cancer stem cell (CSC) properties of breast cancer (42). Increased expression of B4GALNT1 promotes metastasis of lung adenocarcinoma and melanoma (43, 44). B4GALNT1 upregulates glycosylation of CDK11P110 and therefore confers chemoresistance of pancreatic ductal adenocarcinomas (45). Although poly-N-acetyllactosamine and its corresponding glycotransferases (B3GNT2 and B3GNT3) that facilitate PD-L1/PD-1 stabilization and interaction (19–21) showed no changes in response to exogenous E6 expression, the enhanced MAN2A1 expression has been reported to result in the dysfunction of T cells in tumor microenvironment, and its
inhibition enhances the immune response to anti-PD-L1 in human tumors (46). More importantly, HPV16 or HPV18 E6 enhances c-MYC stability via promoting its O-GlcNAcylation on Thr58 (28). Knockdown of O-GlcNAc transferase (OGT) or ST6GAL1 suppresses tumorigenesis and metastasis of HPV18+ cervical cancer Hela cells (28, 35). Hence, alteration of glycosylation is apparently a crucial step for the E6 to initiate and promote cervical cancer progression and urgently needs to be clarified in future.

ST6GAL1, responsible for the terminal α2,6-sialylation of N-glycans, can be upregulated by HPV16 E5 oncoprotein, and its inhibition increases cisplatin sensitivity of HPV18 cervical cancer cells (35, 47). In the present study, we found that ST6GAL1 expression in cervical scraping samples is significantly increased in patients infected with high-risk HPV subtypes (HPV16, HPV18, HPV52, etc.) compared to low-risk subtypes or HPV-negative samples. Because all the samples with various groups of patients (HPV positive and/or negative) were collected from Asian origin, this could represent a limitation. For further studies, possibly multicenter (e.g., American Indian or Alaska Native, Indian, Black or African American, and White ethnicity) and with a larger number of patients (especially in developing countries where cervical cancer is still widespread) will be enrolled. Furthermore, ST6GAL1 positively associates with E6 expression in cervical samples and serves as an important oncogenic mediator in both HPV16 E6-positive and E6-negative C33A cervical cancer cells. Due to having a type I PDZ binding motif (PBM) at the C-terminus, high-risk HPV E6 proteins interacts with many PDZ proteins, like PTPN3, LRCC1, and DLG1, and thus promotes the nuclear localization of transcriptional coactivator YAP1, the major effecter of the Hippo pathway (48). Through mRNA sequencing and associated molecular analysis, we found that YAP1 is a pivotal mediator for E6 to induce ST6GAL1 expression. Taken together, we thus speculated that ST6GAL1 may have an important role in cervical cancer, especially in high-risk HPV-induced carcinogenesis.

**FIGURE 5** | ST6GAL1 activates cGMP/PKG signal axis to play oncogenic activities. (A) C33A cells were transiently transfected with pcDNA3.1-ST6GAL1 overexpressing plasmid (ST6GAL1), empty vector (EV), short hairpin RNA targeting ST6GAL1 (shST6GAL1), or a non-targeting control (shNTC). Forty-eight hours later, expression of classic proteins involved in TGF-β, cGMP/PKG, and Hippo signaling pathways were detected by Western blot. (B) Proliferation of indicated cells were detected by CCK-8 assay. (C) The clones of indicated cells were visualized by crystal violet staining. (D) Statistical analysis of colony numbers in C33A cells received indicated treatment. (E, F) Apoptosis of indicated cells were detected by flow cytometry, and then, apoptotic rates were statistically analyzed. (G, H) Migrative abilities of indicated cells were detected by wound-healing assay and statistically analyzed. (I, J) Invasive abilities of indicated cells were detected by Transwell assay and statistically analyzed. Data were presented as mean ± SD from the three independent replicates. **p < 0.01; ***p < 0.001.
Hippo/YAP signaling pathway plays a critical role in the progression of cervical cancer and can further interact with the ErbB2 and EGFR RTKs to form a positive feedback autocrine/paracrine loop (49). ST6GAL1 endows resistance of cancer cells to gefitinib (EGFR inhibitor) and trastuzumab (anti-ErbB2 antibody) (25) and also confers tumor cell resistance against hypoxia via enhancing hypoxia-inducible factor-1α (HIF-1α) expression (50). Recently, molecular analysis has confirmed that ST6GAL1 decreases the sensitization of cancer cells to trastuzumab-induced cytotoxicity through directly enhancing α2,6-sialylation of ErbB2, which results in the increased activation of both ErbB2 and EGFR RTKs (51). Thus, ST6GAL1 may serve as a linker that bridges Hippo/YAP signaling and RTKs activation. With the fact that hyperactivation of genes involved in Hippo/YAP signaling–RTKs-positive feedback loop occurring in most advanced/recurrent cervical cancer patients (>70%) (9, 49, 52) and directly targeting the HPV-16 E6 has been shown to be ineffective for invasive cancer by itself alone (8), target inhibition of ST6GAL1 may be a promising combinational therapeutic strategy for RTK inhibitors or E6-directed therapies in cervical cancer.

In the present study, since we did not perform in-depth mass spectrometry-based glycomic and glycoproteomic analysis, the exact target proteins of ST6GAL1 cannot be confirmed. However, we found that ST6GAL1 activates cGMP/PKG signaling pathway through ST6GAL1 (Figure 6). (A) C33A and C33A-E6 (E6 stable expressing) cells were transiently transfected with short hairpin RNA targeting ST6GAL1 (shST6GAL1) or a non-targeting control (shNTC). Forty-eight hours later, the expression of cGMP/PKG signaling pathway-related proteins were detected by Western blot. (B) C33A and C33A-E6 cells were transiently transfected with pcDNA3.1-ST6GAL1 overexpressing plasmid (ST6GAL1) or empty vector (EV). Forty-eight hours later, phosphorylated VASP expression in indicated cells were detected by Western blot. (C) Proliferation of indicated cells were detected by MTT assay. (D) The colonies of indicated cells were visualized by crystal violet staining. (E) Statistical analysis of colony numbers in indicated cells. (F, G) Apoptosis of indicated cells were detected by flow cytometry, and then, apoptotic rates were statistically analyzed. (H, I) Migrative abilities of indicated cells were detected by wound-healing assay and statistically analyzed. (J, K) Invasive abilities of indicated cells were detected by Transwell assay and statistically analyzed. Data were presented as mean ± SD from the three independent replicates. **p < 0.01; ***p < 0.001.
may play a sophisticated role in the progression of cervical cancer, and the detailed molecular targets of ST6GAL1 need to be further identified for unveiling its contribution in E6-induced carcinogenesis.

CONCLUSION

In this paper, we demonstrated that high-risk HPV16 E6 oncoprotein induced significant glycosylation alterations in cervical cancer cells. In-depth analyses further revealed that α2,6-sialyltransferase, ST6GAL1, was a novel E6-induced oncogenic protein and performed oncogenic activities in both E6-positive and E6-negative cervical cancer cells. E6 depended on YAP1 to stimulate ST6GAL1 expression and subsequently resulted in the activation of downstream cGMP/PKG pathway. Most importantly, knockdown ST6GAL1 or target inhibition of cGMP/PKG pathway suppressed colony formation and metastasis of cervical cancer cells. Therefore, ST6GAL1 or cGMP/PKG signaling might be novel targets for the development of drugs against cervical cancer.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in https://portal.gdc.cancer.gov/.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of the Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. Olusola P, Banerjee HN, Philley JV, Dasgupta S. Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells (2019) 8(6):622. doi: 10.3390/cells8060622
3. National Institutes of Health. Virus Genome Variants. In PapillomaVirus Episteme. Bethesda, MA, USA: NIH. (2019). Available at: https://pave.niaid.nih.gov/.
4. Bhatt KH, Neller MA, Srihari S, Crooks P, Lekieffre L, Aftab BT, et al. Profiling HPV-16-Specific T Cell Responses Reveals Broad Antigen Reactivities in Oropharyngeal Cancer Patients. J Exp Med (2020) 217(10): e20200389. doi: 10.1084/jem.20200389
5. Long W, Yang Z, Li X, Chen M, Liu J, Zhang Y, et al. HPV-16, HPV-58, and HPV-33 Are the Most Carcinogenic HPV Genotypes in Southwestern China and Their Viral Loads Are Associated With Severity of Premalignant Lesions in the Cervix. Virol J (2018) 15(1):94. doi: 10.1186/s12985-018-1003-x
6. Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc (2020) 112(2):229–32. doi: 10.1016/j.jnma.2020.03.002
7. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi: 10.3332/caac.21338
8. Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol (2019) 5(1):67–73. doi: 10.1001/jamaoncol.2018.4051
9. Burk RD, Chen Z, Salier C, Tarvin K, Carvalho AL, Scapulatempo-Neto C, et al. Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature (2017) 543(7645):378–84. doi: 10.1038/nature21386
10. Kuguyo O, Tisaki N, Thomford NE, Magwati T, Madzziyre MG, Nhachi CFB, et al. Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers? OMICS (2018) 22(7):468–83. doi: 10.1089/omi.2018.0075
11. Tewari KSS, M W, Long HJ. Improved Survival With Bevacizumab in Advanced Cervical Cancer. N Engl J Med (2017) 377(7):702. doi: 10.1056/NEJMoa1700022
12. Li S, Hong X, Wei Z, Xie M, Li W, Liu G, et al. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated F33 Degradation. Front Microbiol (2019) 10:2483. doi: 10.3389/fmicb.2019.02483
13. Katzenellenbogen R. Telomerase Induction in HPV Infection and Oncogenesis. Viruses (2017) 9(7):180. doi: 10.3390/v9070180
14. Thomas M, Myers MP, Massimi P, Guaraccia C, Banks L. Analysis of Multiple HPV E6 PDZ Interactions Defines Type-Specific PDZ Fingerprints That Predict Oncogenic Potential. PloS Pathog (2016) 12(8):e1005766. doi: 10.1371/journal.ppat.1005766
15. Wang Q, Song R, Zhao C, Liu H, Yang Y, Gu S, et al. HPV16 E6 Promotes Cervical Cancer Cell Migration and Invasion by Downregulation of NHERF1. Int J Cancer (2019) 144(7):1619–32. doi: 10.1002/ijc.31876
16. Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, et al. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T
Cells Directed Against E6. Clin Cancer Res (2015) 21(19):4341–9. 
doi: 10.1158/1078-0432.ccr-14-3341

17. Celestin M, Masato G, Cristina M, Mercelli B, Bertagnin C, Sapraski F, et al. A Novel Small-Molecule Inhibitor of the Human Papillomavirus E6-P53 Interaction That Reactivates P53 Function and Blocks Cancer Cells Growth. Cancer Lett (2020) 470:115–25. doi: 10.1016/j.canlet.2019.10.046

18. Mereiter S, Balmafia M, Campos D, Gomes J, Reis CA. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell (2019) 36(1):6–16. doi: 10.1016/j.ccell.2019.06.006

19. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. Removal of N-Linked Glycossylation Enhances PD-L1 Detection and Predicts Anti-PD-1/ PD-L1 Therapeutic Efficacy. Cancer Cell (2019) 36(2):168–78.e4. doi: 10.1016/j.ccell.2019.09.005

20. Li CW, Lim SO, Chung EM, Park AH, Yao J, et al. Eradication of HPV16 E6 in Cervical Cancer. Frontiers in Oncology (2021) 11:716246

21. Qin Y, Zhong Y, Zhu M, Dang L, Yu H, Chen Z, et al. Age- and Sex-Associated Expression of Alpha 2,6-Sialyltransferase ST6Gal I in Cervical Squamous Cell Carcinomas. Cell Death Dis (2020) 11(2):192. doi: 10.1038/s41419-017-0202-5

22. Gong L, Lei Y, Tan X, Dong Y, Luo Z, Zhang D, et al. Propanolol Selectively Inhibits Cervical Cancer Cell Growth by Suppressing the cGMP/PKG Pathway. BioMed Pharmacother (2019) 111:1243–8. doi: 10.1016/j.biopha.2019.01.027

23. Xiang T, Loo JX, Sh X, Xiong W, Guo Y, Ke H, et al. E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the EGFR and C-MET Oncogenes by Destabilizing the Histone Demethylase KDM5C. Cancer Res (2018) 78(6):1418–30. doi: 10.1158/0008-5472.can-17-2118

24. Basuoka O, Sarabia-Vega V, Banks L. Human Papillomavirus Oncoproteins and Post-Translational Modifications: Generating Multifunctional Hubs for Overriding Cellular Homeostasis. Biol Chem (2020) 410(5):585–99. doi: 10.1515/hbch-2019-0408

25. Niederer M, Qian X, Höfler D, Kogosov V, Kaewprag J, Kaufmann AM, et al. Post-Translational Control of IL-1β via the Human Papillomavirus Type 16 E6 Oncoprotein: A Novel Mechanism of Innate Immune Escape Mediated by the E3-Ubiquitin Ligase AIP. Pathog Pattern (2013) 9(8):e1003556. doi: 10.1371/journal.ppat.1003556

26. Pinho SS, Reis CA. Glycosylation in Cancer: Mechanisms and Clinical Implications. Nat Rev Cancer (2015) 15(9):540–55. doi: 10.1038/nrc3989

27. Li, Tai YJ, Chen JI, Liu RJ, Liao GS, Yeo HL, Ho CL, et al. Fucosyltransferase-1 and 2 Play Pivotal Roles in Breast Cancer Cells. Cell Death Dis (2019) 5:74. doi: 10.1038/s41419-019-0145-y

28. Yoshida H, Koodie L, Jacobsen K, Hanzawa K, Yamamoto M. B4GALNT1 Induces Angiogenesis, Anchorage Independence Growth and Motility, and Promotes Tumorigenesis in Melanoma by Induction of Ganglioside GM2/GD2. Sci Rep (2020) 10(1):1199. doi: 10.1038/s41598-019-5132-2

29. Jiang T, Wu H, Lin M, Yin J, Tan L, Ruan Y, et al. B4GALNT1 Promotes Progression and Metastasis in Lung Adenocarcinoma Through JNK/C-Jun/Slug Pathway. Carcinogenesis (2021) 42(4):621–30. doi: 10.1093/carcin/bga141

30. Chen Y, Su L, Huang C, Wu S, Qiu X, Zhao X, et al. Galactosyltransferase 2 Drives Hepatocellular Carcinoma. Oncogene (2020) 40(21):3719–3729. doi: 10.1038/s41380-020-0349-5

31. Shi S, Gu S, Han T, Zhang W, Huang L, Li Z, et al. Inhibition of MAN2A1 Overriding Cellular Homeostasis. Cell Death Dis (2016) 7:979. doi: 10.1038/s41419-016-0221-z

32. Jiang T, Wu H, Lin M, Yin J, Tan L, Ruan Y, et al. B4GALNT1 Promotes Progression and Metastasis in Lung Adenocarcinoma Through JNK/C-Jun/Slug Pathway. Carcinogenesis (2021) 42(4):621–30. doi: 10.1093/carcin/bga141

33. Chen Y, Su L, Huang C, Wu S, Qiu X, Zhao X, et al. Galactosyltransferase 2 Drives Hepatocellular Carcinoma. Oncogene (2020) 40(21):3719–3729. doi: 10.1038/s41380-020-0349-5

34. Wang et al. HPV16 E6 in Cervical Cancer

Macrophages Involved in Mycobacterium Tuberculosis Infection. Tuberculosis (Edinb) (2017) 104:95–106. doi: 10.1016/j.tube.2017.03.010

35. Zhang X, Pan C, Zhou L, Cai Z, Zhao S, Yu D. Knockdown of ST6Gal-I Increases Cisplatin Sensitivity in Cervical Cancer Cells. BMC Cancer (2016) 16 (1):949. doi: 10.1186/s12885-016-2981-y

36. Klotznu S, Anurin A, Nickie B, Regan JL, Lange M, Schulze L, et al. PDE5 Inhibition Eliminates Cancer Stem Cells via Induction of PKA Signaling. Cell Death Dis (2018) 9(2):192. doi: 10.1038/s41419-017-0202-5

37. Chen X, Loo JX, Sh X, Xiong W, Guo Y, Ke H, et al. E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the EGFR and C-MET Oncogenes by Destabilizing the Histone Demethylase KDM5C. Cancer Res (2018) 78(6):1418–30. doi: 10.1158/0008-5472.can-17-2118

38. Basuoka O, Sarabia-Vega V, Banks L. Human Papillomavirus Oncoproteins and Post-Translational Modifications: Generating Multifunctional Hubs for Overriding Cellular Homeostasis. Biol Chem (2020) 410(5):585–99. doi: 10.1515/hbch-2019-0408
53. Liu N, Mei L, Fan X, Tang C, Ji X, Hu X, et al. Phosphodiesterase 5/Protein Kinase G Signal Governs Stemness of Prostate Cancer Stem Cells Through Hippo Pathway. *Cancer Lett* (2016) 378(1):38–50. doi: 10.1016/j.canlet.2016.05.010

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Liu, Cai, Yao, Chen, Song, Yuan, Tan, Hu, Xiang and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.